Gsa Capital Partners LLP Rhythm Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$15.81 - $27.8 $823,685 - $1.45 Million	-52,099 Reduced 75.99%	16,465 $377,000
Q2 2023 Aug 14, 2023	BUY	$16.32 - $21.15 $1.12 Million - $1.45 Million	68,564 New	68,564 $1.13 Million
Q4 2022 Feb 13, 2023	SELL	$22.21 - $30.25 $36,446 - $49,640	-1,641 Reduced 18.05%	7,451 $217,000
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $60,436 - $433,596	-14,055 Reduced 60.72%	9,092 $223,000
Q2 2022 Aug 09, 2022	BUY	$3.12 - $12.25 $72,218 - $283,550	23,147 New	23,147 $96,000

192

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.34B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.